-
Chimerix Inc. NASDAQ:CMRX Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The company's three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.
Location: 2505 Meridian Pkwy Ste 100, North Carolina, 27713-2288, US | Website: www.chimerix.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-68.33M
Cash
148.2M
Avg Qtr Burn
-16.93M
Short % of Float
2.40%
Insider Ownership
6.65%
Institutional Own.
46.20%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TEMBEXA (brincidofovir) Details Smallpox | Approved Quarterly sales | |
ONC201 Details Glioma, Cancer, Brain tumor | Phase 3 Data readout | |
ONC206 Details Brain tumor, Solid tumor/s, Glioblastoma | Phase 1 Data readout | |
Dociparstat sodium (DSTAT) Details Cancer, Acute myeloid leukemia | Failed Discontinued | |
Dociparstat sodium (DSTAT) Details Infectious disease, COVID-19 | Failed Discontinued |